Skip to main content
Fig. 4 | Cost Effectiveness and Resource Allocation

Fig. 4

From: Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china

Fig. 4

Tornado diagram representing the cost per QALY gained in one-way sensitivity analysis for AC-TH strategy versus TCH strategy.The width of the bars represents the range of the results when the variables were changed. The width of the bars represents the range of results when the variables are changed.The vertical dotted line represents the base-case results

Back to article page
\